🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Multiple Myeloma
Clinical trial register · China

Multiple Myeloma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 44 Guangzhou 29 Shanghai 25 Tianjin 22 Hangzhou 20
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China12 Janssen Research & Development, LLC9 GlaxoSmithKline6 Pfizer5 The First Affiliated Hospital of Soochow University4
Site location
Beijing44 Guangzhou29 Shanghai25 Tianjin22 Hangzhou20
All 57 locations
Target enrolment
to

Multiple Myeloma trials in China

126 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997Multiple Myeloma
DrugsIberdomide·Bortezomib·Daratumumab·Dexamethasone
Celgene
Phase 3
939
Changsha, Nanchang, Xi'an, Shanghai, Taiyuan, Wenzhou, Beijing, Changchun
2022-06-23
Active, closed
Cohort Construction and Prognostic Model Construction for Multiple Myeloma
NCT06366802Multiple Myeloma
The First Affiliated Hospital of Soochow University
Observational
1,000
Suzhou
2022-05-03
Recruiting
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
NCT05294055Multiple Myeloma, Lymphoma
DrugsEtoposide·Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
120
Hefei, Beijing, Zhengzhou, Jinan, Tianjin
2022-04-26
Not yet open
A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
NCT05181501Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.
Phase 1
20
Hefei, Changzhou, Nanjing
2022-04
Active, closed
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416Multiple Myeloma
DrugsElranatamab·Lenalidomide
Pfizer
Phase 3
854
Guangzhou, Tianjin, Wenzhou
2022-03-25
Recruiting
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781Multiple Myeloma
DrugCilta-cel
Janssen Research & Development, LLC
Phase 4
295
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
2022-03-09
Active, closed
To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM
NCT05302648Multiple Myeloma
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1
18
Shanghai
2022-02-09
Recruiting
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
NCT04662294Acute Myeloid Leukemia, Non-hodgkin's Lymphoma, Multiple Myeloma
Zhejiang University
Phase EARLY_PHASE1
108
Hangzhou
2021-11-18
Active, closed
A Study of NINLARO® in Chinese Adults With Multiple Myeloma
NCT05013190Multiple Myeloma
Takeda
Observational
72
Hefei, Beijing, Zhengzhou, Hohhot, Suzhou, Nanchang, Shenyang, Qingdao
2021-10-29
Active, closed
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169Multiple Myeloma
DrugsTeclistamab·Pomalidomide·Bortezomib·Daratumumab
Janssen Research & Development, LLC
Phase 3
587
Beijing, Changchun, Changshashi, Chaoyang District, Chengdu, Fuzhou, Guangzhou, Hangzhou
2021-10-14
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236Multiple Myeloma
DrugsDarzalex·Elranatamab·Pomalidomide·Daratumumab
Pfizer
Phase 3
893
Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2021-10-04
Recruiting
Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM
NCT06099912Multiple Myeloma, Frailty
FengYan Jin
Observational
131
Changchun
2021-09-08
Active, closed
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT06868654Multiple Myeloma
DrugsBelantamab mafodotin·Bortezomib·Daratumumab·Dexamethasone
GlaxoSmithKline
Phase 3
72
Beijing, Changchun, Guangzhou, Hangzhou, Jinan, Nanjing, Shenyang, Suzhou
2021-07-28
Recruiting
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
NCT05283993Multiple Myeloma, Amyloidosis, Cryoglobulinemia, Castleman's Disease
Peking University First Hospital
Observational
2,000
Beijing
2021-07-01
Recruiting
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
NCT04776330Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse
Chongqing Precision Biotech Co., Ltd
Phase 1/2
80
Kunming
2021-03-07
Recruiting
National Longitudinal Cohort of Hematological Diseases
NCT04645199Multiple Myeloma, Acute Myeloid Leukemia, Hemophilia, Hemophilia A
Institute of Hematology & Blood Diseases Hospital, China
Observational
2,300
Tianjin
2020-12-01
Active, closed
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623Multiple Myeloma
DrugsBelantamab mafodotin·Pomalidomide·Bortezomib·Dexamethasone
GlaxoSmithKline
Phase 3
302
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Jiangsu, Nanchang, Shenyang
2020-10-01
Recruiting
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
NCT04504526Lymphoma, Multiple Myeloma, Leukemia
Drug68Ga-pentixafor
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1
50
Fuzhou
2020-08-07
Active, closed
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT04246047Multiple Myeloma
DrugsBelantamab mafodotin·Bortezomib·Daratumumab·Dexamethasone
GlaxoSmithKline
Phase 3
494
Beijing, Jinan, Shenyang
2020-05-07
Active, closed
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04162210Multiple Myeloma
DrugsBelantamab mafodotin·Dexamethasone
GlaxoSmithKline
Phase 3
325
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Nanchang, Shenzhen, Tianjin
2020-04-02
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
DrugsVenclexta·Venetoclax
AbbVie
Phase 3
165
2019-09-06
Recruiting
Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
NCT04025450Multiple Myeloma
DrugChidamide
The First Affiliated Hospital of Soochow University
Phase 1/2
50
Suzhou
2019-07-15
Recruiting
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
NCT04271644Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse
Chongqing Precision Biotech Co., Ltd
Phase 1/2
80
Kunming
2019-04-01
Active, closed
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
NCT03539744Multiple Myeloma
DrugsPomalidomide·Venetoclax·Dexamethasone
AbbVie
Phase 3
265
Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang, Shenyang
2018-10-22
By invitation
AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities
NCT07410403Multiple Myeloma
Fuling Zhou
Observational
10
Wuhan
2018-08-01
Recruiting
Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma
NCT03196414Multiple Myeloma
The First Affiliated Hospital of Soochow University
Phase 1/2
10
Suzhou
2016-09
Rows per page Showing 101–126 of 126
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/condition/multiple-myeloma?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 126 of those studies listing the condition Multiple Myeloma.

How many Multiple Myeloma trials are recruiting in China?

91 of the 126 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 12 have not yet opened recruitment, 22 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.